Good Morning All, There is much stated and implied in

New Post Public Reply Private Reply Replies (0) Message Board
Kgem
407
Good Morning All ,

There is much stated and implied in Doctor Dalton’s LinkedIn post regarding all our affiliates and partners. Refer to post #5303 by Mikeyt or use this link:

https://investorshangout.com/post/view?id=5335748

I do not understand the reference to FACEBOOK in this list, because FACEBOOK does not allow CBD advertising. In fact, some say FACEBOOK has declared war on CBD. However, there are indirect means of advertising that are allowed, and they can funnel customers to a CBD website. More will need to be explained about this reference in the future. The remainder of this list is impressive, and some might even say the list is excessive. So, can Univec really become so large, and wouldn’t they be a billion dollar plus behemoth nearly overnight? The answer is yes they could and likely will.

You see, Dalton already has the 70,000 plus pharmacies to sell his products, he processes the pharmacy orders and handles their billing. Insurance coverage is assured because Doctor Dalton heads the NCPDP and therefore writes the rules governing insurance coverage. CARF accreditation (similar to FDA approval) is the highest accreditation a cannabis company can get, because the FDA does not yet consider CBD a medicine. Finally, Doctor Dalton made the brilliant move of gaining access to the Veterans Administration product procurement system. This means the Univec cannabis transdermal patch is approved for treating medical issues such as opioid addiction, PTSD, anxiety disorder, sleep disorder, brain trauma, and a whole host of other medical ailments including cancer, multiple sclerosis, Parkinson’s, and on and on. While trials and treatments are conducted, documentation of the effects are required as mandated by Congress. This means treatment programs are a part of the research schedule Congress insists on. For those who do not know, government programs are HUGE, and this alone could make Univec a billion dollar company.

TELADOC is also mentioned in this list. TELADOC is the wave of the future when it comes to personal health care, and both Doctor Dalton and Doctor Mitchell are heavily involved in it. In fact, they have been pioneers in TELADOC development for many years. The TELADOC system allows clients to interact with a healthcare professional via the internet, and treatments are prescribed on the spot while the patient is monitored for heartbeat, blood pressure, and other key health markers --- all while sitting in the comfort of one's home and away from the germs and viruses so often encountered in healthcare facilities.

Patient Assistance Programs and StarterScripts is also listed. Patient Assistance Programs sounds to me like government programs. While StarterScripts is a secure documentation system developed by Doctor Dalton and it instantly documents and verifies each individual using the system so as to prevent fraud and misrepresentation. A secure documentation and verification system is mandated by many states already, and may soon be adopted on the Federal level. Once again, a brilliant move by Doctor Dalton.

The “Conglomeration of Companies” Doctor Dalton mentioned includes Univec, AGRiMED, Sativeo, and I understand Hemp Commodity Industries as well. However, Dalton lists MRMD (MariMed) and HARVEST in addition to our core group of companies. This suggests much more will be revealed as the conglomeration progresses toward its ultimate goal.

The future looks bright --- very bright indeed.


Kgem



Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 121

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 138

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 206

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 110

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading

Top 5 Most Recently Viewed Articles

Massive Trading Activity Spotted in Tempus AI (TEM) Options

Updated Category News Views 292

Unprecedented Trading Interest in Tempus AI Options Investors with significant capital are showing a strong bullish outlook on Tempus AI (TEM). This surge in trading activity is something every retail trader should pay attention to. Identifying Smart Money Moves Today, we observed notable trends in the options market for Tempus AI, highlighting the actions of big-money...

Continue Reading
Endeavour Mining Sees Significant Stake Notification from BlackRock

Updated Category News Views 143

Endeavour Mining and Major Shareholding Update Endeavour Mining plc is making headlines with its latest update regarding shareholders. Recently, the company received a notable notification from BlackRock, Inc., one of the world’s leading investment management firms. This announcement highlights BlackRock's interests in Endeavour Mining, showcasing the ongoing...

Continue Reading
Adverity Unveils Innovative Data Quality Suite for Clients

Updated Category News Views 188

Adverity launched its Data Quality Suite a while back, promising to revolutionize how businesses tackle data management. But let’s dig deeper—what’s the real deal here? Data Quality: A Marketing Essential or Just Noise? In this digital mess we call life, clean data isn’t just a luxury; it’s an absolute necessity. Back then, marketing and analytics teams faced a...

Continue Reading
Strengthening Medical Connections Between U.S. and Jordan

Updated Category News Views 225

Strengthening Medical Collaborations Dr. Maen Hussein, a talented medical oncologist and hematologist, recently held an important meeting with King Abdullah II of Jordan. This gathering aimed to enhance the collaboration between medical professionals in both the United States and Jordan, showcasing the commitment to elevate healthcare standards through shared knowledge...

Continue Reading
Alphabet's Stock Outlook Amid DOJ Challenges: Key Insights

Updated Category News Views 101

Alphabet's Price Target Change: Implications Recently, Evercore ISI adjusted its price target for Alphabet Inc. (NASDAQ: GOOGL), reducing it from $225 to $200. Even with this decrease, Evercore retains an Outperform rating for the stock. This change signals growing concerns over the ongoing antitrust trials led by the Department of Justice (DOJ), which could heavily...

Continue Reading